TytoCare is a virtual healthcare technology company that develops FDA-cleared handheld medical exam devices and AI-powered software platforms to enable high-quality remote physical exams, replicating in-office visits from home or professional settings.[1][3][5] It serves patients, healthcare providers, health plans, hospitals, clinics, and insurers by addressing access gaps in primary and specialty care, particularly for rural or underserved populations, through its Home Smart Clinic (for at-home use) and Pro Smart Clinic (for clinics, schools, and workplaces).[2][4][5] The solution solves the problem of limited healthcare access by allowing guided self-exams for heart, lungs, ears, throat, skin, and vitals, with real-time or asynchronous clinician review, driving outcomes like 7% lower care costs, 24% fewer ED visits, and 5x higher utilization than video-only telehealth.[4][5]
Growth momentum is strong, with over 240 healthcare organizations, 1.6M patients, and 40K providers on the platform, plus partnerships like Sanford Health (deploying 180 units to cut wait times to 5.1 minutes) and recognition for innovation.[2][4][5]
TytoCare emerged to bridge the disconnect between homes and healthcare, focusing on replicating doctors' physical exams for families facing primary care access challenges, especially for acute or chronic conditions anywhere in the world.[7] While specific founders are not detailed in available sources, the company was founded with a mission to transform primary and specialty care via telehealth, starting with user-friendly handheld devices and a digital platform for remote diagnostics.[1][5] Early traction came from FDA clearances for its devices and AI features, partnerships with major health systems like Sanford and Prisma Health, and studies validating impact, such as a 2023 Journal of Health Economics analysis showing cost reductions in a large HMO.[2][4][9]
Pivotal moments include developing the Home and Pro Smart Clinic solutions, Tyto Insights AI for guided exams and diagnosis support, and scaling to global adoption with CE and FDA 510K validations built on vast clinical data.[4][6]
TytoCare rides the telehealth and AI-driven remote care wave, accelerated by post-pandemic demand for accessible, home-based diagnostics amid clinician shortages and rural care gaps.[1][2][5] Timing is ideal as audio/video telehealth proves insufficient for physical exams, while regulatory nods (FDA/CE clearances) and data from 1.6M+ patients fuel AI advancements in clinical intelligence.[4][6] Market forces like rising healthcare costs, aging populations, and value-based care favor its model, which diverts expensive ER visits and integrates with health plans for scalable deployment.[4] It influences the ecosystem by setting standards for hybrid care—elevating homes/clinics as care hubs—and enabling providers to extend reach without quality loss, as seen in Sanford's rural expansions.[2]
TytoCare is poised to dominate AI-augmented telehealth with expanding Clinical Intelligence Agents, leveraging its data moat for deeper diagnostics in chronic care and predictive insights.[5][6] Trends like multimodal AI, home health normalization, and payer shifts to virtual-first models will propel growth, potentially doubling partnerships amid regulatory tailwinds. Its influence may evolve from niche innovator to ecosystem backbone, fully embedding remote exams in standard care and further slashing costs—transforming the home into healthcare's new frontier, as envisioned from its access-focused origins.[1][7]
TytoCare has raised $99.0M in total across 2 funding rounds.
TytoCare's investors include Aglae Ventures, Andreessen Horowitz, Cyberstarts VC, Greenoaks Capital, Index Ventures, Insight Partners, Lightspeed Venture Partners, Hans Tung, Salesforce Ventures, Sequoia Capital, SoftBank Investment Advisers, Bernard Arnault.
TytoCare has raised $99.0M across 2 funding rounds. Most recently, it raised $49.0M Series E in August 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2023 | $49.0M Series E | Aglae Ventures, Andreessen Horowitz, Cyberstarts VC, Greenoaks Capital, Index Ventures, Insight Partners, Lightspeed Venture Partners, Hans Tung, Salesforce Ventures, Sequoia Capital, SoftBank Investment Advisers, Bernard Arnault, Howard Schultz | |
| Apr 1, 2020 | $50.0M Series D | Aglae Ventures, Andreessen Horowitz, Cyberstarts VC, Greenoaks Capital, Index Ventures, Insight Partners, Lightspeed Venture Partners, Hans Tung, Salesforce Ventures, Sequoia Capital, SoftBank Investment Advisers, Bernard Arnault, Howard Schultz |
